17-10-11　ⓔ文献

  1. 日本血液学会・日本リンパ網内系学会編：造血器腫瘍取扱い規約 2010年3月 第1版，金原出版，2010.

  2. Swerdlow SH, Campo E, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition), IARC, 2017.

  3. National Cancer Institute sponsored study of classifications of non–Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage: The Non–Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982; 49: 2112–2135.

  4. DeVita VT, Hellman S, et al, eds: Cancer: Principles and Practice of Oncology, 3rd ed, Lippincott: 1989.

  5. 国立がん研究センターがん情報サービス：がん登録・統計.

  6. Muto R, Miyoshi H, et al: Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. Cancer Med, 2018; 7: 5843–5858.

  7. Cheson BD, Fisher RI, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non–Hodgkin lymphoma: the Lugano classification. J Clin Oncol, 2014; 32: 3059–3068.

  8. The International Non–Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non–Hodgkin’s lymphoma. N Engl J Med, 1993; 329: 987–994.

  9. Alizadeh AA, Eisen MB, et al: Distinct types of diffuse large B–cell lymphoma identified by gene expression profiling. Nature, 2000; 403: 503–511.

  10. Fisher RI, Gaynor ER, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med, 1993; 328: 1002–1006.

  11. Coiffier B, Thieblemont C, et al: Long–term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab–CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l’Adulte. Blood, 2010; 116: 2040–2045.

  12. Pfreundschuh M, Trumper L, et al: CHOP–like chemotherapy plus rituximab versus CHOP–like chemotherapy alone in young patients with good–prognosis diffuse large–B–cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol, 2006; 7: 379–391.

  13. Persky DO, Unger JM, et al: Phase II study of rituximab plus three cycles of CHOP and involved–field radiotherapy for patients with limited–stage aggressive B–cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol, 2008; 26: 2258–2263.

  14. Sehn LH, Gascoyne RD: Diffuse large B–cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood, 2015; 125: 22–32.

  15. Philip T, Guglielmi C, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy–sensitive non–Hodgkin’s lymphoma. N Engl J Med, 1995; 333: 1540–1545.

  16. Schuster SJ, Bishop MR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse large B–cell lymphoma. N Engl J Med, 2019; 380: 45–56.

  17. Neelapu SS, Locke FL, et al: Axicabtagene ciloleucel CAR T–cell therapy in refractory large B–cell lymphoma. N Engl J Med, 2017; 377: 2531–2544.

  18. Abramson JS, Palomba ML, et al: Lisocabtagene maraleucel for patients with relapsed or refractory large B–cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, 2020; 396: 839–852.

  19. Solal-Céligny P, Roy P, et al: Follicular lymphoma international prognostic index. Blood, 2004; 104: 1258–1265.

  20. Federico M, Bellei M, et al: Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol, 2009; 27: 4555–4562.

  21. Solal–Céligny P, Lepage E, et al: Doxorubicin–containing regimen with or without interferon alfa–2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol, 1998; 16: 2332–2338.

  22. 日本血液学会編：造血器腫瘍診療ガイドライン 2018年版補訂版，金原出版，2020.

  23. Wotherspoon AC, Doglioni C, et al: Regression of primary low–grade B–cell gastric lymphoma of mucosa–associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 1993; 342: 575–577.

  24. Magrath I, Adde M, et al: Adults and children with small non–cleaved–cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol, 1996; 14: 925–934.

  25. Maruyama D, Watanabe T, et al: Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX–M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol, 2010; 92: 732–743.

  26. Thomas DA, Faderl S, et al: Chemoimmunotherapy with hyper–CVAD plus rituximab for the treatment of adult Burkitt and Burkitt–type lymphoma or acute lymphoblastic leukemia. Cancer, 2006; 106: 1569–1580.

  27. Vose J, Armitage J, et al: International peripheral T–cell and natural killer/T–cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol, 2008; 26: 4124–4130.

  28. Horwitz S, O'Connor OA, et al: Brentuximab vedotin with chemotherapy for CD30–positive peripheral T–cell lymphoma (ECHELON–2): a global, double–blind, randomised, phase 3 trial. Lancet, 2019; 393: 229–240.

  29. Yamaguchi M, Tobinai K, et al: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T–cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol, 2009; 27: 5594–5600.

  30. Yamaguchi M, Kwong YL, et al: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T–cell lymphoma, nasal type: the NK–Cell Tumor Study Group study. J Clin Oncol, 2011; 29: 4410–4416.